- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04827992
Evaluation of Medical Cannabis and Prescription Opioid Taper Support for Reduction of Pain and Opioid Dose in Patients With Chronic Non-Cancer Pain
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This trial is a randomized, six-month study of medical marijuana (MM) on opioid use that will: (1) evaluate whether adults with chronic, non-cancer pain on COT assigned to MM+POTS, compared with those assigned to WL+POTS, have greater reduction in opioid dose and/or pain intensity and interference, (2) assess whether participants assigned to MM+POTS, compared with those assigned to WL+POTS, have improved quality of life, depression, and anxiety; and reduced self-reported opioid dose, (3) evaluate whether those assigned to MM+POTS develop symptoms of CUD and have a reduced number of OUD symptoms over the 24-week intervention, as well as at the 12-month time point.
Participants will be randomly assigned to either an active MM arm (n = 125), or to a waitlist control arm (WLC) (n = 125). Participants will be assessed at baseline, every 4 weeks for 6 months, and at a 12-month follow-up for opioid use, development of CUD, development or resolution of OUD, and neurocognitive performance. Urine collected will be assessed with quantitative assays.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Jodi Gilman, PhD
- Phone Number: 6176437293
- Email: jgilman1@mgh.harvard.edu
Study Locations
-
-
Maine
-
Portland, Maine, United States, 04102
- Recruiting
- Maine Medical Center
-
Principal Investigator:
- Aurora Quaye, MD
-
Contact:
- Aurora Quaye, MD
- Email: aurora.quaye@spectrumhcp.com
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02114-2523
- Recruiting
- Massachusetts General Hospital
-
Contact:
- Jodi Gilman
- Phone Number: 617-643-7293
- Email: jgilman1@partners.org
-
Cambridge, Massachusetts, United States, 02139
- Active, not recruiting
- Cambridge Health Alliance
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Men and women aged 18-75, inclusive.
- Endorsing > 6 months of chronic, non-cancer pain.
- On stable prescription opioid doses of 25 MME or greater for >90 days, verified by the Prescription Monitoring Program.
- Either no prior use or current light cannabis use (weekly or less in the past 12 months).
- Plans to use medical cannabis for pain to control pain and/or reduce opioid dose.
- Competent and willing to provide written informed consent in English.
- Potential participants of childbearing potential must have a negative urine pregnancy test at enrollment and agree to use effective contraception: abstinence; hormonal contraception; intra-uterine device, sterilization; or double barrier contraception, during the study.
Exclusion Criteria:
- Current cannabis use (including inhaled or ingested CBD products) of greater than weekly on average in the past 12 months, assessed via self-report (no more than 10 times in the past 90 days).
- Current cannabis use disorder; current moderate to severe substance use disorder for any substance by structured interview, EXCEPT nicotine and opioids (OUD).
- Current uncontrolled major medical illness, such as cancer, symptomatic hypothyroidism/hyperthyroidism or severe respiratory compromise.
- Use of non-prescribed opioids, by self-report.
- Dose change or initiation of medications with significant analgesic effects (e.g., tricyclic antidepressants, SSRIs, gabapentin, NSAIDs) in the past 4 weeks.
- Concomitant medications will be discussed at each study visit, and any medications that may interact with cannabinoids (e.g., warfarin) will be discussed with a study clinician prior to enrollment or continued participation.
- Actively suicidal and/or suicide attempt or psychiatric hospitalization in past year, or current suicidal ideation with specific plan or intent.
- History of intellectual disability (e.g., Down's syndrome) or other severe developmental disorder or IQ < 70.
- Current diagnosis of delirium, dementia, amnestic, or other cognitive disorder; current diagnosis of bipolar II disorder; lifetime diagnosis of bipolar I disorder, schizophrenia spectrum, or other psychotic disorder.
- Surgery within the past month or planned during the next 6 months.
- Pregnant or trying to get pregnant or breastfeeding.
- In the opinion of the investigator or study physicians, not able to complete study procedures or safely participate in this study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Medical Marijuana + Prescription Opioid Taper Support (POTS) behavioral treatment
This group can begin using medical marijuana immediately and will participate in the POTS treatment groups.
|
Patients in this group can choose what type, how much, and when to use medical marijuana to use.
Other Names:
Prescription Opioid Taper Support (POTS), a manualized behavioral prescription opioid taper support intervention developed by consultant, will be offered weekly to all participants to support behavioral self-management of pain and structured, voluntary taper of COT dose.
|
Active Comparator: Prescription Opioid Taper Support (POTS) treatment alone
This group must abstain from marijuana use and will participate in the POTS behavioral treatment alone.
|
Prescription Opioid Taper Support (POTS), a manualized behavioral prescription opioid taper support intervention developed by consultant, will be offered weekly to all participants to support behavioral self-management of pain and structured, voluntary taper of COT dose.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mean Difference in Prescription Monitoring Program verified opioid dose at baseline and week 24
Time Frame: Baseline and week 24
|
Opioid dose verified by the Prescription Monitoring Program, in morphine milligram equivalents (MME) per day.
If participants decide to reduce dose at week 24, we will use the reduced dose even if the new dose cannot be immediately implemented (e.g., due to delays in refilling prescription) to ensure accurate representation of change.
|
Baseline and week 24
|
Mean Difference in Pain, Enjoyment, General Activity (PEG) Scale Summed Score over post-baseline to week 24 interval
Time Frame: Every post-baseline day until week 24
|
The Pain, Enjoyment, General Activity (PEG) scale will assess pain intensity and interference.
The scale ranges from 0-30, with a higher score indicating greater pain intensity and interference.
Collected daily by a self-reported online survey.
|
Every post-baseline day until week 24
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mean Difference in Quality of Life Enjoyment and Satisfaction Questionnaire - Short Form Summed Score at weeks 4, 8, 12, 16, 20, 24
Time Frame: Week 4, week 8, week 12, week 16, week 20, week 24
|
Quality of Life Enjoyment and Satisfaction Questionnaire - Short Form will assess changes in quality of life measures.
The scale ranges from 14 - 70, with a lower score indicating greater dissatisfaction with life.
|
Week 4, week 8, week 12, week 16, week 20, week 24
|
Mean Difference in PROMIS-29 Depression Subscale Summed Score at weeks 4, 8, 12, 16, 20, 24
Time Frame: Week 4, week 8, week 12, week 16, week 20, week 24
|
The 8-item depression subscale of the Patient-Reported Outcomes Measurement Information System (PROMIS)-29 will be used to assess depression symptoms.
The scale uses a t-score metric (mean of 50, SD of 10).
Higher scores indicate worse depression.
|
Week 4, week 8, week 12, week 16, week 20, week 24
|
Mean Difference in PROMIS-29 Anxiety Subscale Summed Score at weeks 4, 8, 12, 16, 20, 24
Time Frame: Week 4, week 8, week 12, week 16, week 20, week 24
|
The 7-item anxiety subscale of the Patient-Reported Outcomes Measurement Information System (PROMIS)-29 will be used to assess anxiety symptoms.
The scale uses a t-score metric (mean of 50, SD of 10).
Higher scores indicate worse anxiety.
|
Week 4, week 8, week 12, week 16, week 20, week 24
|
Mean Difference in Opioid Use Disorder Symptoms at weeks 4, 8, 12, 16, 20, 24
Time Frame: Week 4, week 8, week 12, week 16, week 20, week 24
|
The DSM-5 Opioid Use Disorder Checklist will evaluate symptoms of Opioid Use Disorder (number of symptoms).
The scale ranges from 0 - 11, with a higher score indicating more severe Opioid Use Disorder.
|
Week 4, week 8, week 12, week 16, week 20, week 24
|
Mean Difference in Cannabis Use Disorder Symptoms at weeks 4, 8, 12, 16, 20, 24
Time Frame: Week 4, week 8, week 12, week 16, week 20, week 24
|
The DSM-5 Cannabis Use Disorder Checklist will evaluate symptoms of Cannabis Use Disorder (number of symptoms).
The scale ranges from 0 - 11, with a higher score indicating more severe Cannabis Use Disorder.
|
Week 4, week 8, week 12, week 16, week 20, week 24
|
Mean Difference in Self-Reported Opioid Dose at weeks 4, 8, 12, 16, 20, 24
Time Frame: Week 4, week 8, week 12, week 16, week 20, week 24
|
Self-reported opioid dose in morphine milligram equivalents (MME) per day.
This is collected daily by a self-reported online survey and averaged over each 4-week interval.
|
Week 4, week 8, week 12, week 16, week 20, week 24
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2021P000871
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ICF
- ANALYTIC_CODE
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pain
-
Flowonix MedicalApproved for marketingBack Pain | Leg Pain | Trunk Pain | Intractable Pain | Arm Pain
-
University Hospital Schleswig-HolsteinZealand University Hospital; European Regional Development Fund; Design School...CompletedPain, Acute | Pain, Chronic | Pain Measurement | Pain, CancerGermany
-
Dr. Negrin University HospitalCompletedPostoperative Pain, Acute | Postoperative Pain, ChronicSpain
-
George Washington UniversityRecruitingCervical Fusion | Pain, Back | Pain, Neck | Myofacial PainUnited States
-
Universitat Jaume ICompletedPain, Acute | Pain, Chronic | OncologySpain
-
Atatürk Chest Diseases and Chest Surgery Training...RecruitingPostoperative Pain | Postoperative Pain, Acute | Postoperative Pain, Chronic | VATSTurkey
-
Dow University of Health SciencesRecruitingLow Back Pain | Chronic Low-back Pain | Low Back Pain, Mechanical | Mechanical Low Back Pain | Pain, Chronic | Pain, Back | Lower Back Pain Chronic | CLBP - Chronic Low Back PainPakistan
-
Janssen Research & Development, LLCCompletedPain, Radiating | Pain, Burning | Pain, Crushing | Pain, Migratory | Pain, SplittingUnited States, France, Spain, Poland, Portugal
-
susanne beckerSNSFCompletedLow Back Pain | Pain, Acute | Pain, ChronicSwitzerland
-
University of Campinas, BrazilCompletedPREGNANCY | LUMBAR BACK PAIN | PELVIC PAIN
Clinical Trials on Medical Marijuana
-
HaEmek Medical Center, IsraelTechnion, Israel Institute of Technology; Syqe MedicalNot yet recruitingChemotherapy-induced Peripheral NeuropathyIsrael
-
Children's Hospital of PhiladelphiaWithdrawnInflammatory Bowel Diseases | Neuropathic Pain
-
Massachusetts General HospitalCompletedDepression | Pain | Insomnia | AnxietyUnited States
-
Florida State UniversityCompleted
-
Colorado State UniversityWilliam R. Shaffer, M.D.CompletedMultiple SclerosisUnited States
-
University Health Network, TorontoShoppers Drug Mart; integrated medhealth communicationRecruitingDepression | Epilepsy | Pain | Sleep | AnxietyCanada
-
Barth WilseyNational Institute on Drug Abuse (NIDA); University of California, San Diego; VA Northern California Health Care SystemCompletedSpinal Cord Diseases | Spinal Cord InjuriesUnited States
-
The Connecticut Hospice Inc.Completed
-
OMNI Medical Services, LLCOMNI Medical Services IncRecruitingDepression | COVID-19 | Epilepsy | Multiple Sclerosis | Glaucoma | Cancer | Covid19 | Chronic Pain | Parkinson Disease | Inflammatory Bowel Diseases | Hepatitis C | Insomnia | HIV/AIDS | Amyotrophic Lateral Sclerosis | Fibromyalgia | Anxiety | Bipolar Disorder | Seizures | Crohn Disease | Traumatic Brain Injury | Ulcerative Colitis | Sickle... and other conditionsUnited States
-
New York State Psychiatric InstituteNational Institute on Drug Abuse (NIDA)CompletedMarijuana DependenceUnited States